Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, Board Director of Levicept and Chair of Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
An important limitation in many social media threads on statins is the relatively short time horizon of the studies discussed.
Statins don’t just reduce cardiovascular events over years; their benefits accumulate over decades, including prevention of disability, preservation of
Cardiology calls statins miracle drugs. Social media calls them poison.
Both sides cite published scientific papers. How can they be looking at the same evidence and reaching opposite conclusions?
As a cardiologist, I think both sides are are on to something. Let me explain.
Our CEO @paulpetertak spoke with @endpts reporter @Nicole_DeFeudis about new long-term follow-up data from our phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized #ProstateCancer.
https://endpoints.news/candel-reports-prostate-cancer-drugs-long-term-data-ahead-of-fda-filing/
$CADL #Immunotherapy #CancerResearch
Patients with localized Prostate Cancer want more than treatment, they want to live free from cancer while maintaining quality of life.
Excellent discussion from #AUA2026 with Dr. Mark Garzotto and patient advocate Tom Hulsey on aglatimagene besadenovec (CAN-2409), the phase 3
